Aligos Therapeutics (NASDAQ:ALGS) Announces Earnings Results

Aligos Therapeutics (NASDAQ:ALGS) released its earnings results on Monday. The company reported ($3.41) EPS for the quarter, missing analysts’ consensus estimates of ($2.63) by ($0.78), Zacks reports. Aligos Therapeutics had a negative return on equity of 114.34% and a negative net margin of 1,283.19%.

Aligos Therapeutics Trading Down 10.0 %

NASDAQ:ALGS opened at $11.65 on Monday. The firm has a market capitalization of $41.80 million, a price-to-earnings ratio of -0.86 and a beta of 2.52. Aligos Therapeutics has a 1-year low of $6.76 and a 1-year high of $46.80. The business’s 50-day moving average price is $27.25 and its two-hundred day moving average price is $20.58.

About Aligos Therapeutics

Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).